Open for inclusion

A phase 1/2 dose escalation safety, pharmacokinetic and efficacy study of multiple intravenous administration of a human monoclonal antibody (SAR6509848) against CD38 in patients with selected CD38+ hematological malignancies

Cancer type: Hematological malignancies

Phase: I/II

Principal Investigator: Anttila Pekka

Country: FI

Keywords: Finland, Helsinki, SAR6509848

Status: Open for inclusion

Link to